64674 The impact of continuous secukinumab treatment through week 104 on patient reported outcomes in patients with moderate to severe hidradenitis suppurativa: A post hoc analysis of the SUNSHINE and SUNRISE core and extension trials
Alexa B. Kimball(Beth Israel Deaconess Medical Center), Jacek C. Szepietowski(Wroclaw Medical University), Maryam Shayesteh Alam(Barrie Urology Group), Bertrand Paguet, Łukasz Matusiak(Wrocław University of Science and Technology), Steven Daveluy(Wayne State University), Valeria Jordan M, Christelle C Pieterse, Lauren A.V. Orenstein(Emory University), Georgios Kokolakis(Humboldt-Universität zu Berlin), D. Ioannides(Hospital Venereal and Skin Diseases Thessaloniki)
Cited by 0
Related Papers
European S1 guideline for the treatment of hidradenitis suppurativa/acne inversa
|Journal of the European Academy of Dermatology and Venereology|2015|1.1k
The Psychological Burden of Skin Diseases: A Cross-Sectional Multicenter Study among Dermatological Out-Patients in 13 European Countries
|Journal of Investigative Dermatology|2014|954
Clinical Classification of Itch: a Position Paper of the International Forum for the Study of Itch
|Acta Dermato Venereologica|2007|748